AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

Search

TPG Specialty Lending Inc

Open

BrancheFinanzen

23.7 -0.34

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

23.49

Max

23.94

Schlüsselkennzahlen

By Trading Economics

Einkommen

-14M

37M

Verkäufe

49M

114M

KGV

Branchendurchschnitt

12.693

25.916

Dividendenrendite

8.51

Gewinnspanne

32.44

EBITDA

-17M

64M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+0.96% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

8.51%

3.70%

Nächste Dividendenausschüttung

29. Sept. 2025

Nächstes Ex-Dividendendatum

15. Sept. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

279M

2.3B

Vorheriger Eröffnungskurs

24.04

Vorheriger Schlusskurs

23.7

Nachrichtenstimmung

By Acuity

20%

80%

29 / 536 Ranking in Finance

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

TPG Specialty Lending Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Aug. 2025, 21:42 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4. Aug. 2025, 21:21 UTC

Ergebnisse
Wichtige Markttreiber

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4. Aug. 2025, 20:45 UTC

Ergebnisse

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4. Aug. 2025, 19:15 UTC

Wichtige Markttreiber

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4. Aug. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Aug. 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4. Aug. 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4. Aug. 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4. Aug. 2025, 21:30 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. Aug. 2025, 21:21 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4. Aug. 2025, 21:18 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. Aug. 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4. Aug. 2025, 20:25 UTC

Ergebnisse

Transocean 2Q Loss $938M >RIG

4. Aug. 2025, 20:25 UTC

Ergebnisse

Transocean 2Q Loss/Shr $1.06 >RIG

4. Aug. 2025, 20:18 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4. Aug. 2025, 20:15 UTC

Ergebnisse

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4. Aug. 2025, 20:13 UTC

Ergebnisse

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4. Aug. 2025, 20:09 UTC

Ergebnisse

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4. Aug. 2025, 20:06 UTC

Ergebnisse

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4. Aug. 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4. Aug. 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4. Aug. 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4. Aug. 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer-Vergleich

Kursveränderung

TPG Specialty Lending Inc Prognose

Kursziel

By TipRanks

0.96% Vorteil

12-Monats-Prognose

Durchschnitt 24.14 USD  0.96%

Hoch 25 USD

Tief 23 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für TPG Specialty Lending Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

7 ratings

7

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

20.83 / 21.65Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

29 / 536 Ranking in Finanzen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über TPG Specialty Lending Inc

Sixth Street Specialty Lending, Inc. (NYSE: TSLX) is a business development company. The fund provides senior secured loans (first-lien, second-lien, and unitranche), unsecured loans, mezzanine debt, and investments in corporate bonds and equity securities and structured products, non-control structured equity, and common equity with a focus on co-investments for organic growth, acquisitions, market or product expansion, restructuring initiatives, recapitalizations, and refinancing. The fund invests in business services, software & technology, healthcare, energy, consumer & retail, manufacturing, industrials, royalty related businesses, education, and specialty finance. It seeks to finance and lending to middle market companies principally located in the United States. The fund invests in companies with enterprise value between $50 million and $1 billion or more and EBITDA between $10 million and $250 million. The transaction size is between $15 million and $350 million. The fund invests across the spectrum of the capital structure and can arrange syndicated transactions of up to $500 million and hold sizeable positions within its credits.